ReviewDiabetes, obesity & metabolism2015
Biosimilar insulins: a European perspective.
Review in Diabetes, obesity & metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.PloS one · 2018Pooled it
- Biosimilar insulins: Narrative review of the regulatory framework and registration studies.Diabetes, obesity & metabolism · 2025Review
- Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Nanomedical Relevance of the Intermolecular Interaction Dynamics-Examples from Lysozymes and Insulins.ACS omega · 2019Article
- Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2019Review
- The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective.Therapeutic advances in endocrinology and metabolism · 2018Article
- How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?Clinical diabetes : a publication of the American Diabetes Association · 2017Article
- Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?European journal of hospital pharmacy : science and practice · 2017Article
- Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.PharmacoEconomics · 2016Article
- Biosimilar Insulins - What a Clinician Needs to Know?Indian journal of endocrinology and metabolismReview
- Article
- Biosimilar insulins: An unavoidable option in South-East Asia.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarizes the current biosimilars approved in Europe and the key clinical issues associated with the use of biosimilar insulins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.